id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-D-0369-0585,FDA,FDA-2007-D-0369,Draft Guidance on Alprazolam; Revised Guidance; PSG_021726,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:34Z,,1,0,0900006484e387f6
FDA-2007-D-0369-0586,FDA,FDA-2007-D-0369,Draft Guidance on Colesevelam Hydrochloride; Revised Guidance; PSG_021176,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:34Z,,1,0,0900006484e387f8
FDA-2007-D-0369-0572,FDA,FDA-2007-D-0369,Draft Guidance on Leuprolide Acetate; Revised Guidance; PSG_021088,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:32Z,,1,0,0900006484e387dc
FDA-2007-D-0369-0613,FDA,FDA-2007-D-0369,Draft Guidance on Lactitol; New Guidance; PSG_211281,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:38Z,,1,0,0900006484e38839
FDA-2007-D-0369-0606,FDA,FDA-2007-D-0369,Draft Guidance on Metoclopramide Hydrochloride; Revised Guidance; PSG_022246,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:37Z,,1,0,0900006484e3882b
FDA-2007-D-0369-0603,FDA,FDA-2007-D-0369,Draft Guidance on Desloratadine; Revised Guidance; PSG_021312,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:37Z,,1,0,0900006484e38825
FDA-2007-D-0369-0615,FDA,FDA-2007-D-0369,Draft Guidance on Cenobamate; New Guidance; PSG_212839,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:39Z,,1,0,0900006484e3883d
FDA-2007-D-0369-0591,FDA,FDA-2007-D-0369,Draft Guidance on Riluzole; New Guidance; PSG_209080,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:35Z,,1,0,0900006484e38802
FDA-2007-D-0369-0578,FDA,FDA-2007-D-0369,Draft Guidance on Dicyclomine Hydrochloride; New Guidance; PSG_007409-Tab,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:33Z,,1,0,0900006484e387e8
FDA-2007-D-0369-0580,FDA,FDA-2007-D-0369,Draft Guidance on Ondansetron; Revised Guidance; PSG_020781,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:33Z,,1,0,0900006484e387ec
FDA-2007-D-0369-0588,FDA,FDA-2007-D-0369,Draft Guidance on Loratadine; Revised Guidance; PSG_020704,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:35Z,,1,0,0900006484e387fc
FDA-2007-D-0369-0589,FDA,FDA-2007-D-0369,Draft Guidance on Minocycline Hydrochloride; New Guidance; PSG_209269,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:35Z,,1,0,0900006484e387fe
FDA-2007-D-0369-0569,FDA,FDA-2007-D-0369,Draft Guidance on Artesunate; New Guidance; PSG_213036,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:32Z,,1,0,0900006484e37440
FDA-2007-D-0369-0610,FDA,FDA-2007-D-0369,Draft Guidance onColesevelam Hydrochloride; Revised Guidance; PSG_022362,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:38Z,,1,0,0900006484e38833
FDA-2007-D-0369-0608,FDA,FDA-2007-D-0369,Draft Guidance on Minocycline Hydrochloride; New Guidance; PSG_213690,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:38Z,,1,0,0900006484e3882f
FDA-2007-D-0369-0614,FDA,FDA-2007-D-0369,Draft Guidance on Pemigatinib; New Guidance; PSG_213736,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:39Z,,1,0,0900006484e3883b
FDA-2007-D-0369-0594,FDA,FDA-2007-D-0369,Draft Guidance on Bempedoic Acid; New Guidance; PSG_211616,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:35Z,,1,0,0900006484e38808
FDA-2007-D-0369-0600,FDA,FDA-2007-D-0369,Draft Guidance on Cetirizine Hydrochloride; Revised Guidance; PSG_022578,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:36Z,,1,0,0900006484e3881f
FDA-2007-D-0369-0590,FDA,FDA-2007-D-0369,Draft Guidance on Olanzapine; Revised Guidance; PSG_021086,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:35Z,,1,0,0900006484e38800
FDA-2007-D-0369-0597,FDA,FDA-2007-D-0369,Draft Guidance on Tenapanor Hydrochloride; New Guidance; PSG_211801,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:36Z,,1,0,0900006484e38818
FDA-2007-D-0369-0609,FDA,FDA-2007-D-0369,Draft Guidance on Carbidopa; Levodopa; Revised Guidance; PSG_076699,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:38Z,,1,0,0900006484e38831
FDA-2007-D-0369-0593,FDA,FDA-2007-D-0369,Draft Guidance on Lansoprazole; Revised Guidance; PSG_021428,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:35Z,,1,0,0900006484e38806
FDA-2007-D-0369-0612,FDA,FDA-2007-D-0369,Draft Guidance on Opicapone; New Guidance;  PSG_212489,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:38Z,,1,0,0900006484e38837
FDA-2007-D-0369-0567,FDA,FDA-2007-D-0369,Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,Notice,Notice of Availability,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,2022-01-11T04:59:59Z,2021-12-31T02:00:32Z,2021-24431,0,0,0900006484e37a93
FDA-2007-D-0369-0575,FDA,FDA-2007-D-0369,Draft Guidance on Leuprolide Acetate; Norethindrone Acetate; Revised Guidance; PSG_203696,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:32Z,,1,0,0900006484e387e2
FDA-2007-D-0369-0568,FDA,FDA-2007-D-0369,Draft Guidance on Beclomethasone Dipropionate Monohydrate; New Guidance; PSG_019389,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:31Z,,1,0,0900006484e3743e
FDA-2007-D-0369-0574,FDA,FDA-2007-D-0369,Draft Guidance on Remimazolam Besylate; New Guidance; PSG_212295,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:32Z,,1,0,0900006484e387e0
FDA-2007-D-0369-0582,FDA,FDA-2007-D-0369,Draft Guidance on Sodium Iodide I-131; New Guidance; PSG_016517,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:34Z,,1,0,0900006484e387f0
FDA-2007-D-0369-0587,FDA,FDA-2007-D-0369,Draft Guidance on Tucatinib; New Guidance; PSG_213411,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:34Z,,1,0,0900006484e387fa
FDA-2007-D-0369-0571,FDA,FDA-2007-D-0369,Draft Guidance on Triamcinolone Acetonide; Revised Guidance; PSG_012041,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:32Z,,1,0,0900006484e387da
FDA-2007-D-0369-0573,FDA,FDA-2007-D-0369,Draft Guidance on Ciclesonide; New Guidance; PSG_022004,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:32Z,,1,0,0900006484e387de
FDA-2007-D-0369-0576,FDA,FDA-2007-D-0369,Draft Guidance on Donepezil Hydrochloride; Revised Guidance; PSG_021720,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:33Z,,1,0,0900006484e387e4
FDA-2007-D-0369-0581,FDA,FDA-2007-D-0369,Draft Guidance on Minocycline Hydrochloride; New Guidance; PSG_212379,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:33Z,,1,0,0900006484e387ee
FDA-2007-D-0369-0583,FDA,FDA-2007-D-0369,Draft Guidance on Risperidone; Revised Guidance; PSG_021444,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:34Z,,1,0,0900006484e387f2
FDA-2007-D-0369-0595,FDA,FDA-2007-D-0369,Draft Guidance on Glucagon; New Guidance; PSG_212097,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:36Z,,1,0,0900006484e38814
FDA-2007-D-0369-0598,FDA,FDA-2007-D-0369,"Draft Guidance on Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic; New Guidance; PSG_212832",Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:36Z,,1,0,0900006484e3881a
FDA-2007-D-0369-0607,FDA,FDA-2007-D-0369,Draft Guidance on Bempedoic Acid; Ezetimibe; New Guidance; PSG_211617,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:37Z,,1,0,0900006484e3882d
FDA-2007-D-0369-0599,FDA,FDA-2007-D-0369,Draft Guidance on Diclofenac Potassium; New Guidance; PSG_020142,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:36Z,,1,0,0900006484e3881c
FDA-2007-D-0369-0601,FDA,FDA-2007-D-0369,Draft Guidance on Colesevelam Hydrochloride; New Guidance; PSG_210895,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:37Z,,1,0,0900006484e38821
FDA-2007-D-0369-0602,FDA,FDA-2007-D-0369,Draft Guidance on Clascoterone; New Guidance; PSG_213433,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:37Z,,1,0,0900006484e38823
FDA-2007-D-0369-0577,FDA,FDA-2007-D-0369,Draft Guidance on Mirtazapine; Revised Guidance; PSG_021208,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:33Z,,1,0,0900006484e387e6
FDA-2007-D-0369-0584,FDA,FDA-2007-D-0369,"Draft Guidance on Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic; New Guidance; PSG_212121",Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:34Z,,1,0,0900006484e387f4
FDA-2007-D-0369-0596,FDA,FDA-2007-D-0369,Draft Guidance on Lemborexant; New Guidance; PSG_212028,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:36Z,,1,0,0900006484e38816
FDA-2007-D-0369-0604,FDA,FDA-2007-D-0369,Draft Guidance on Draft Guidance on Lurbinectedin; New Guidance; PSG_213702,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:37Z,,1,0,0900006484e38827
FDA-2007-D-0369-0605,FDA,FDA-2007-D-0369,Draft Guidance on Rimegepant Sulfate; New Guidance; PSG_212728,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:37Z,,1,0,0900006484e38829
FDA-2007-D-0369-0611,FDA,FDA-2007-D-0369,Draft Guidance on Zolmitriptan; Revised Guidance; PSG_021231,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:38Z,,1,0,0900006484e38835
FDA-2007-D-0369-0592,FDA,FDA-2007-D-0369,Draft Guidance on Rizatriptan Benzoate; Revised Guidance; PSG_020865,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:35Z,,1,0,0900006484e38804
FDA-2007-D-0369-0570,FDA,FDA-2007-D-0369,Draft Guidance on Aripiprazole; Revised Guidance; PSG_021729,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:32Z,,1,0,0900006484e387d8
FDA-2007-D-0369-0579,FDA,FDA-2007-D-0369,Draft Guidance on Methylphenidate; Revised Guidance; PSG_205489,Other,Guidance,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,,2024-11-07T00:33:33Z,,1,0,0900006484e387ea
FDA-2007-D-0369-0561,FDA,FDA-2007-D-0369,"Product-Specific Guidances for Ferric Oxyhydroxide; Revised Draft
Guidances for Industry; Availability",Notice,Notice of Availability,2021-09-17T04:00:00Z,2021,9,2021-09-17T04:00:00Z,2021-11-17T04:59:59Z,2021-11-18T02:00:11Z,2021-20064,0,0,0900006484d8c141
FDA-2007-D-0369-0560,FDA,FDA-2007-D-0369,"Product-Specific Guidances; Draft and 
Revised Draft Guidances for Industry; 
Availability",Notice,Notice of Availability,2021-08-23T04:00:00Z,2021,8,2021-08-23T04:00:00Z,2021-10-23T03:59:59Z,2021-10-21T01:00:31Z,2021-18072,0,0,0900006484c9bafb
FDA-2007-D-0369-0558,FDA,FDA-2007-D-0369,Product-Specific Guidance for Olodaterol Hydrochloride; Tiotropium Bromide; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2021-07-28T04:00:00Z,2021,7,2021-07-28T04:00:00Z,2021-09-28T03:59:59Z,2021-09-25T01:00:52Z,2021-16046,0,0,0900006484c14747
FDA-2007-D-0369-0554,FDA,FDA-2007-D-0369,Product-Specific Guidance for Cilastatin Sodium; Imipenem; Relebactam; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2021-07-19T04:00:00Z,2021,7,2021-07-19T04:00:00Z,2021-09-18T03:59:59Z,2021-08-05T20:00:36Z,2021-15170,0,0,0900006484c01943
FDA-2007-D-0369-0555,FDA,FDA-2007-D-0369,"Draft Guidance on Cilastatin Sodium; Imipenem; Relebactam
July 2021",Other,Guidance,2021-07-19T04:00:00Z,2021,7,2021-07-19T04:00:00Z,,2021-07-30T18:56:04Z,,0,0,0900006484c01d82
FDA-2007-D-0369-0550,FDA,FDA-2007-D-0369,Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,Notice,Notice of Availability,2021-05-20T04:00:00Z,2021,5,2021-05-20T04:00:00Z,2021-07-20T03:59:59Z,2021-08-11T01:00:51Z,2021-10589,0,0,0900006484b23761
FDA-2007-D-0369-0548,FDA,FDA-2007-D-0369,Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,Notice,Notice of Availability,2021-03-29T04:00:00Z,2021,3,2021-03-29T04:00:00Z,2021-05-25T03:59:59Z,2021-03-29T12:28:38Z,2021–06202,0,0,0900006484a84f91
FDA-2007-D-0369-0547,FDA,FDA-2007-D-0369,Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,Notice,Notice of Availability,2021-03-25T04:00:00Z,2021,3,2021-03-25T04:00:00Z,2021-05-25T03:59:59Z,2021-05-25T01:00:43Z,2021-06202,0,0,0900006484a7a413